AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03953170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teduglutide
Description: Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA.
Study NCT03953170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05112328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exocrine Pancreatic Enzyme
Description: Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
Study NCT05112328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
Study NCT04049331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
Description: first two doses four weeks apart; following three more doses every ten weeks.
Study NCT04049331 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: first two doses four weeks apart; following three more doses every ten weeks.
Study NCT04774081 — intervention group
Intervention type: DEVICE
Intervention: 24h Continuous glucose monitoring and urinary C-peptide collection
Description: Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
Study NCT06259695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Aquatic Therapy Prosthesis
Description: We will recruit up to three participants, who will attend up to two fitting appointments lasting up to one hour to assist in the design development. After the design of the prosthesis is completed, participants will attend three, 30-minute, aquatic therapy sessions with a physical therapist trained in aquatic therapy and utilize the prosthesis.
Study NCT06428448 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: REMEDY Spectrum IM Spacer Nail
Description: The REMEDY SPECTRUM IM Spacer Nail is a single-use implant made of polymethylmethacrylate (PMMA) which is internally reinforced with a stainless-steel core (ASTM F138, ISO 5832-1). The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin.~The nail has a slot at the distal end and can be combined with the surgeon's choice of fixation to prevent migration depending on the anatomy of the patient. The REMEDY SPECTRUM IM Spacer Nail is available in two lengths (150mm and 300mm) to accommodate variations in patient anatomy. The distal end has a threaded recess for mating with the optional distal cap, as well as the insertion and removal tools.
Study NCT04553263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave 8Mg-90Mg Extended-Release Tablet
Description: Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
Study NCT04553263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
Study NCT05790564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond
Description: Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
Study NCT05790564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crackers
Description: Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
Study NCT05151042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wafer-less approach
Description: Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates.
Study NCT05151042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Guided orthognathic surgery using occlusal wafers
Description: Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates.
Study NCT05064111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TRUS biopsy
Description: The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.
Study NCT06625853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mtwo R files with Xp-Endo finisher file
Description: XP-endo Finisher file will be inserted without rotation into the root canals filled with 2.5% NaOCl and will be activated (800 rpm; torque of 1 N.cm) for~1 min in each canal using slow and gentle 7-8 mm lengthwise movements.
Study NCT06625853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mtwo R files
Description: obturation material will be removed using Mtwo R (VDW, Munich, Germany)files attached to an endodontic motor (Ecube, seachin, Korea) with a constant speed of 280 rpm, as suggested by the manufacturer. Mtwo R 25/0.05 will be used to empty the coronal and middle thirds of the root. Mtwo R 15/0.05 will be used to reach the working length.
Study NCT06624410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the Vocalization domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital.
Study NCT05197257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-PSMA-11
Description: The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
Study NCT05713812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotape will be applied
Study NCT05713812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Treatment
Description: IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
Study NCT06020664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-1416+SOC
Description: NOX1416+SOC as provided in Arm/group description
Study NCT06020664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+SOC
Description: Placebo+SOC as provided in Arm/group description
Study NCT05246072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin + colchicine
Description: In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
Study NCT05246072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
Study NCT05461014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBI
Description: The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness.
Study NCT06001281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: plasma collection
Description: Plasma samples will be prospectively collected at relevant time points during patient treatment.
Study NCT04676126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumega-Z
Description: Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
Study NCT04676126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide Hcl 2% Oph Soln
Description: Topical carbonic anhydrase inhibitor
Study NCT04676126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
Study NCT04804267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
Study NCT04804267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LINZESS®
Description: Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
Study NCT04804267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo orally once daily
Study NCT06417177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a placebo in pill form.
Study NCT06417177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Participants will receive oral propranolol (1 mg/kg).
Study NCT06417177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtesa
Description: Participants will receive oral gemtesa (75 mg).
Study NCT05555225 — intervention group
Intervention type: OTHER
Intervention: Methylome
Description: Epigenetic study : analysis of DNA methylation
Study NCT06059690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pH Measurement of in vivo tissue
Description: The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
Study NCT06452199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis
Description: 1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.
Study NCT06452199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.
Study NCT05893147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: De-escalation VS No De-escalation
Description: No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic.
Study NCT05893147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral beta-lactams VS non beta-lactams
Description: Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.
Study NCT05893147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central vascular catheter retention VS Central vascular catheter replacement
Description: Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed.
Study NCT05893147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin VS Carbapenem for low risk AmpC organisms
Description: Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses
Study NCT05893147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up blood culture VS No routine follow-up blood culture
Description: Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria
Study NCT06061081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH3739937
Description: VH3739937 will be administered.
Study NCT06061081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT05671744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cell-based non-invasive prenatal testing
Description: Blood sampling
Study NCT05657990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
Study NCT05845567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
Study NCT05845567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
Study NCT06648018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional information
Description: Written nutritional information about food with high content of iron.
Study NCT06648018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-succinate
Description: 100 mg of Iron-succinate per day.
Study NCT05098119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, Nab-paclitaxel, Carboplatin
Description: Neoadjuvant Therapy
Study NCT05098119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Standard of care
Study NCT05098119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Adjuvant Therapy
Study NCT06341543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).
Description: The QF-CMV will be performed in all participants.
Study NCT06341543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).
Description: The QF-CMV will be performed in all participants.
Study NCT06341543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication of the result of the QF-CMV to the clinician in charge
Description: The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge.
Study NCT05763875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: 284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
Study NCT05763875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
Study NCT05763875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for Inclisiran
Description: 0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
Study NCT05763875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Inclisiran
Description: 0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
Study NCT05763875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Ezetimibe
Description: 0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
Study NCT05763875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Ezetimibe
Description: 0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
Study NCT05028075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cobalt +
Description: Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
Study NCT05773651 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
Study NCT06575179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine low-dose
Description: The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.
Study NCT06575179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: The control group received volume-matched 0.9% saline infusions at identical rates.